2014肿瘤研究与临床Requires access

Comparison between the effect of SOX regimen and FOLFOX4 regimen for advanced gastric cancer

Yuejun Li, Debin Zhuo

Open publisher page 0 citations

Abstract

Objective To compare the efficacy and toxicity of SOX and FOLFOX4 regimen in the treatment of advanced gastric cancer.Methods Total of 32 patients with advanced gastric cancer proved pathologically were randomly divided into 2 groups:16 patients received SOX regimen [oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1,S-1 capsules 80 mg/(m-2·d) twice a day per oral from day 1 to day 14 every 3 weeks],the other 16 patients received FOLFOX4 regimen [oxaliplatin 85 mg/m2 as a 2-hour infusion on day 1 and a 2-hour infusion of LV 200/(m2· d) followed by a 5-Fu bolus 400/(m2· d) and 22-hour infusion 600/(m2· d) for 2 consecutive days every 2 weeks].Efficacy was evaluated at least 2 cycles.Results The response rates of SOX group and FOLFOX4 group were 56.25 % (9/16) and 43.57 % (7/16),the disease control rates were 81.25 % (13/16) and 75.00 % (12/16).The median progress free survival times were 7.2 months and 5.6 months,the median overall survival times were 9.4 months and 7.9 months.The main toxicity in the two groups was hematological toxicity,nausea/vomiting,and peripheral neuropathy.The main grade 3 hematologic toxicity was neutropenia,with no significant difference between them [12.50 % (2/16) vs 31.25 % (5/16),P =0.394].Conclusions Both SOX and FOLFOX4 regimens are effective for patients with advanced gastric cancer.Compared with FOLFOX4 regimen,SOX regimen is better tolerated for advanced gastric cancer with longer progress free survival and overall survival. Key words: Stomach neoplasms;  Antineoplastic combined chemotherapy protocols

About this research paper

What this paper is about

Objective To compare the efficacy and toxicity of SOX and FOLFOX4 regimen in the treatment of advanced gastric cancer.Methods Total of 32 patients with advanced gastric cancer proved pathologically were randomly divided into 2 groups:16 patients received SOX regimen [oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1,S-1 capsules 80 mg/(m-2·d) twice a day per oral from day 1 to day 14 every 3 weeks],the other 16 patients received FOLFOX4 regimen [oxaliplatin 85 mg/m2 as a 2-hour infusion on day 1 and a 2-hour infusion of LV 200/(m2· d) followed by a 5-Fu bolus 400/(m2· d) and 22-hour infusion 600/(m2· d) for 2 consecutive days every 2 weeks].Efficacy was evaluated at least 2 cycles.Results The response rates of SOX group and FOLFOX4 group were 56.25 % (9/16) and 43.57 % (7/16),the disease control rates were 81.25 % (13/16) and 75.00 % (12/16).The median progress free survival times were 7.2 months and 5.6 months,the median overall survival times were 9.4 months and 7.9 months.The main toxicity in the two groups was hematological toxicity,nausea/vomiting,and peripheral neuropathy.The main grade 3 hematologic toxicity was neutropenia,with no significant difference between them [12.50 % (2/16) vs 31.25 % (5/16),P =0.394].Conclusions Both SOX and FOLFOX4 regimens are effective for patients with advanced gastric cancer.Compared with FOLFOX4 regimen,SOX regimen is better tolerated for advanced gastric cancer with longer progress free survival and overall survival. Key words: Stomach neoplasms;  Antineoplastic combined chemotherapy protocols

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To compare the efficacy and toxicity of SOX and FOLFOX4 regimen in the treatment of advanced gastric cancer.Methods Total of 32 patients with advanced gastric cancer proved pathologically were randomly divided into 2 groups:16 patients received SOX regimen [oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1,S-1 capsules 80 mg/(m-2·d) twice a day per oral from day 1 to day 14 every 3 weeks],the other 16 patients received FOLFOX4 regimen [oxaliplatin 85 mg/m2 as a 2-hour infusion on day 1 and a 2-hour infusion of LV 200/(m2· d) followed by a 5-Fu bolus 400/(m2· d) and 22-hour infusion 600/(m2· d) for 2 consecutive days every 2 weeks].Efficacy was evaluated at least 2 cycles.Results The response rates of SOX group and FOLFOX4 group were 56.25 % (9/16) and 43.57 % (7/16),the disease control rates were 81.25 % (13/16) and 75.00 % (12/16).The median progress free survival times were 7.2 months and 5.6 months,the median overall survival times were 9.4 months and 7.9 months.The main toxicity in the two groups was hematological toxicity,nausea/vomiting,and peripheral neuropathy.The main grade 3 hematologic toxicity was neutropenia,with no significant difference between them [12.50 % (2/16) vs 31.25 % (5/16),P =0.394].Conclusions Both SOX and FOLFOX4 regimens are effective for patients with advanced gastric cancer.Compared with FOLFOX4 regimen,SOX regimen is better tolerated for advanced gastric cancer with longer progress free survival and overall survival. Key words: Stomach neoplasms;  Antineoplastic combined chemotherapy protocols

Key concepts: Regimen, Medicine, Oxaliplatin, Gastroenterology, Neutropenia, Toxicity, Bolus (digestion), Nausea

Related papers

Back to paper searchBrowse research topicsOriginal source
Comparison between the effect of SOX regimen and FOLFOX4 regimen for advanced gastric cancer — Research Paper | ScholarLens